Title of study


Case-Control Study on Parkinson's Disease Among Mutualité Sociale Agricole Affliates in Five Départements

Acronym for cohort


PARTAGE

Name of Principal Investigator - Title


Dr

Name of Principal Investigator - First name


Alex

Name of Principal Investigator - Last name


Elbaz

Address of institution -Institution


INSERM

Address of institution - Street address


16 Avenue Paul Vaillant Couturier

Address of institution - City


VILLEJUIF

Address of institution - Postcode


94807

Country


France

Website


Contact email


[email protected]

Funding source


ANR - ANSES - France Parkinson

Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?


Parkinson's disease

Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)


To study the association of professional exposure to pesticides with Parkinson's disease and the role of gene-environment interactions

Q2b. What distinguishes this case-control study from other studies?


Study performed in farmers from five French regions. Population-based

Q3a. i) Number of publications that involve use of your cohort to date


5

Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)


Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available


1. Ahmed, I., P. C. Lee, C. M. Lill, S. Searles Nielsen, F. Artaud, L. G. Gallagher, M. A. Loriot, C. Mulot, M. Nacfer, T. Liu, J. M. Biernacka, S. Armasu, K. Anderson, F. M. Farin, C. F. Lassen, J. Hansen, J. H. Olsen, L. Bertram, D. M. Maraganore, H. Checkoway, B. Ritz and A. Elbaz (2014). "Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease." PLoS Genet 10(11): e1004788. 2. Ahmed, I., R. Tamouza, M. Delord, R. Krishnamoorthy, C. Tzourio, C. Mulot, M. Nacfer, J. C. Lambert, P. Beaune, P. L. Puig, M.-A. Loriot, D. Charron and A. Elbaz (2012). "Association between Parkinson's Disease and the HLA-DRB1 Locus." Mov Disord 27(9): 1104-1110. 3. Moisan, F., V. Gourlet, J. L. Mazurie, J. L. Dupupet, J. Houssinot, M. Goldberg, E. Imbernon, C. Tzourio and A. Elbaz (2011). "Prediction model of Parkinson's disease based on antiparkinsonian drug claims." Am J Epidemiol 174(3): 354-363. 4. Moisan, F., J. Spinosi, L. Delabre, V. Gourlet, J. L. Mazurie, I. Benatru, M. Goldberg, M. G. Weisskopf, E. Imbernon, C. Tzourio and A. Elbaz (2015). "Association of Parkinson's Disease and Its Subtypes with Agricultural Pesticide Exposures in Men: A Case-Control Study in France." Environ. Health Perspect 123(11): 1123-1129. 5. Moisan, F., J. Spinosi, J. L. Dupupet, L. Delabre, J. L. Mazurie, M. Goldberg, E. Imbernon, C. Tzourio and A. Elbaz (2011). "The relation between type of farming and prevalence of Parkinson's disease among agricultural workers in five French districts." Movement Disord 26(2): 271-279.

Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study


Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:


18

Q4a. Study criteria: what is the age range of participants at recruitment? To:


until death

Q4b. Study criteria: what are the inclusion criteria?


Cases are selected according to consumption of anti-Parkinson's medication or long-term Parkinson's disease. Controls are randomly selected from affiliates of the same funds, matched according to age, gender and département of residence.

Q4c. Study criteria: what are the exclusion criteria?


Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?


1,001-5,000

Q5b. What is the expected number of control participants?


501-1,000

Q6a. Please describe what measures are used to characterise participants


Clinical examination

Q6b. Are there additional measures for participants with the clinical disorder?


MMSE

Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?


If YES please specify


Q7. What is the study design?


Nested case control|Age|Sex

Q8. Are your cases matched by


Q9a. Does your study includes a specialised subset of control participants?


No

Q9b. If your study includes a specialised subset of control participants please describe


Q10a. Is data collection for this study


Closed to new patients

Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?


Q11. Are data collected


Only through the study|Through links to other records or registers(drug claim databases)

Q12. Is there a system in place to enable re-contact with patients for future studies?


No

Q13a. Please give information on data stored in a database (1)


Data summarised in database

% Available


Q13a. Please give information on data stored in a database (2)


No

% Available


Q13a. Please give information on data stored in a database (3)


No

% Available


Q13a. Please give information on data stored in a database (4)


No

% Available


Q13a. Please give information on data stored in a database (5)


No

% Available


Please specify language used


% Available


Q13b. Please give information on how data is held as individual records


No

% Available


Q14a. Are data available to other groups?


Yes

Q14b. If data is available to other groups what is the access policy/mechanisms for access?


Apply to PI or co-ordinator at resource

Q15. What data sharing policy is specified as a condition of use?


No policy exists

Q16a. Are tissues/samples/DNA available to other groups?


No

Q16b i) If yes, please describe below


Q16b. ii) In what form are tissues/samples/DNA supplied?


Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?


No

Q17. Is information on biological characteristics available to other groups?


No

Export as PDF